4
Changes in Ownership
Roivant Sciences Ltd. Filed Acc 0001635088-26-000044
President & Immunovant CEO sold 200,000 shares at $29.59 ($5,918,000)
- President & Immunovant CEO acquired 200,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Venker Eric · President & Immunovant CEO
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-04-20 | Exercise or conversion : show line 1 in the form 10b5-1 | +200,000 | $3.85 | $770,000 | 1,847,546 | D |
| 2026-04-20 | Sale : show line 2 in the form 10b5-1 | −200,000 | $29.59 | $5,918,000 | 1,647,546 | D |
| Open-market sales · 200,000 sh · avg $29.59 · $5,918,000 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-04-20 | Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (Right to Buy) | −200,000 | 4,644,834 | D |
Loading xslF345X06/wk-form4_1776896865.xml…